Treatment of chronic kidney diseases with histone deacetylase inhibitors

Frontiers in Physiology

Volumn 6, Issue APR, 2015, Pages

  Liu, Na ^a   Zhuang, Shougang ^a,b,c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Chronic kidney diseases; Histone deacetylases; Renal fibroblasts; Renal fibrosis

Indexed keywords

ARISTOLOCHIC ACID; BUTYRIC ACID; ENTINOSTAT; FR 276457; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; METHYL 4 (PHENYLTHIO)BUTANOATE; NICOTINAMIDE; POLYCYSTIN 1; POLYCYSTIN 2; SELISISTAT; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SK 7041; TACROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME INHIBITION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84930671996     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00121     Document Type: Review

References (72)

1. Acharya, M. R., Sparreboom, A., Venitz, J., and Figg, W. D. (2005). Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 68, 917-932. doi: 10.1124/mol.105.014167.
2. Advani, A., Huang, Q., Thai, K., Advani, S. L., White, K. E., Kelly, D. J., et al. (2011). Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am. J. Pathol. 178, 2205-2214. doi: 10.1016/j.ajpath.2011.01.044.
3. Alderaan, K., Sekicki, V., Magder, L. S., and Petri, M. (2015). Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol. Int. 35, 701-708. doi: 10.1007/s00296-014-3129-5.
4. Bush, E. W., and McKinsey, T. A. (2010). Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ. Res. 106, 272-284. doi: 10.1161/CIRCRESAHA.109.209338.
5. Cao, Y., Semanchik, N., Lee, S. H., Somlo, S., Barbano, P. E., Coifman, R., et al. (2009). Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl. Acad. Sci. U.S.A. 106, 21819-21824. doi: 10.1073/pnas.0911987106.
6. Chang, M. Y., Parker, E., Ibrahim, S., Shortland, J. R., Nahas, M. E., Haylor, J. L., et al. (2006). Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol. Dial. Transplant 21, 2078-2084. doi: 10.1093/ndt/gfl150.
7. Chen, J., Chen, J. K., and Harris, R. C. (2014). EGF receptor deletion in podocytes attenuates diabetic nephropathy. J. Am. Soc. Nephrol. doi: 10.1681/ASN.2014020192. [Epub ahead of print].
8. Chen, S., and El-Dahr, S. S. (2013). Histone deacetylases in kidney development: implications for disease and therapy. Pediatr. Nephrol. 28, 689-698. doi: 10.1007/s00467-012-2223-8.
9. Chen, Y. T., Chang, F. C., Wu, C. F., Chou, Y. H., Hsu, H. L., Chiang, W. C., et al. (2011). Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 80, 1170-1181. doi: 10.1038/ki.2011.208.
10. Debelle, F. D., Vanherweghem, J. L., and Nortier, J. L. (2008). Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74, 158-169. doi: 10.1038/ki.2008.
11. Dokmanovic, M., and Marks, P. A. (2005). Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96, 293-304. doi: 10.1002/jcb.20532.
12. Du, B., Ma, L. M., Huang, M. B., Zhou, H., Huang, H. L., Shao, P., et al. (2010). High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584, 811-816. doi: 10.1016/j.febslet.2009.12.053.
13. Edens, R. E., Dagtas, S., and Gilbert, K. M. (2006). Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6, 1673-1681. doi: 10.1016/j.intimp.2006.07.001.
14. Fan, L. X., Li, X., Magenheimer, B., Calvet, J. P., and Li, X. (2012). Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 81, 76-85. doi: 10.1038/ki.2011.296.
15. Gabow, P. A. (1993). Autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 22, 511-512.
16. Gilbert, R. E., Huang, Q., Thai, K., Advani, S. L., Lee, K., Yuen, D. A., et al. (2011). Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int. 79, 1312-1321. doi: 10.1038/ki.2011.39.
17. Glozak, M. A., Sengupta, N., Zhang, X., and Seto, E. (2005). Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23. doi: 10.1016/j.gene.2005.09.010.
18. Harris, P. C., and Torres, V. E. (2014). Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J. Clin. Invest. 124, 2315-2324. doi: 10.1172/JCI72272.
19. Johnstone, R. W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299. doi: 10.1038/nrd772.
20. Khan, S., and Jena, G. (2014). Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-β1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem. Toxicol. 73, 127-139. doi: 10.1016/j.fct.2014.08.010.
21. Kim, J. I., Jung, K. J., Jang, H. S., and Park, K. M. (2013). Gender-specific role of HDAC11 in kidney ischemia-and reperfusion-induced PAI-1 expression and injury. Am. J. Physiol. Renal Physiol. 305, F61-F70. doi: 10.1152/ajprenal.00015.2013.
22. Kinugasa, F., Nagatomi, I., Nakanishi, T., Noto, T., Mori, H., Matsuoka, H., et al. (2009). Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl. Immunol. 21, 198-202. doi: 10.1016/j.trim.2009.04.006.
23. Kinugasa, F., Yamada, T., Noto, T., Matsuoka, H., Mori, H., Sudo, Y., et al. (2008). Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol. Pharm. Bull. 31, 1723-1726. doi: 10.1248/bpb.31.1723.
24. Kwon, H. K., Ahn, S. H., Park, S. H., Park, J. H., Park, J. W., Kim, H. M., et al. (2009). A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells. Biol. Pharm. Bull. 32, 1723-1727. doi: 10.1248/bpb.32.1723.
25. Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T. P., and Comb, M. J. (2008). HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J. Biol. Chem. 283, 12686-12690. doi: 10.1074/jbc. C700185200.
26. Lin, C. L., Lee, P. H., Hsu, Y. C., Lei, C. C., Ko, J. Y., Chuang, P. C., et al. (2014). MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J. Am. Soc. Nephrol. 25, 1698-1709. doi: 10.1681/ASN.2013050527.
27. Liu, N., Guo, J. K., Pang, M., Tolbert, E., Ponnusamy, M., Gong, R., et al. (2012a). Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23, 854-867. doi: 10.1681/ASN.2011050493.
28. Liu, N., He, S., Ma, L., Ponnusamy, M., Tang, J., Tolbert, E., et al. (2013). Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE 8:e54001. doi: 10.1371/journal.pone.0054001.
29. Liu, W., Fan, L. X., Zhou, X., Sweeney, W. E. Jr., Avner, E. D., and Li, X. (2012b). HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS ONE 7:e49418. doi: 10.1371/journal.pone.0049418.
30. Ma, X., Ezzeldin, H. H., and Diasio, R. B. (2009). Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911-1934. doi: 10.2165/11315680-000000000-00000.
31. Mahalingam, D., Medina, E. C., Esquivel, J. A. 2nd., Espitia, C. M., Smith, S., Oberheu, K., et al. (2010). Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153. doi: 10.1158/1078-0432.CCR-09-1385.
32. Manson, S. R., Song, J. B., Hruska, K. A., and Austin, P. F. (2014). HDAC dependent transcriptional repression of Bmp-7 potentiates TGF-beta mediated renal fibrosis in obstructive uropathy. J. Urol. 191, 242-252. doi: 10.1016/j.juro.2013.06.110.
33. Marks, P. A., Richon, V. M., Miller, T., and Kelly, W. K. (2004). Histone deacetylase inhibitors. Adv. Cancer Res. 91, 137-168. doi: 10.1016/S0065-230X(04)91004-4.
34. Marks, P. A., Richon, V. M., and Rifkind, R. A. (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216. doi: 10.1093/jnci/92.15.1210.
35. Marumo, T., Hishikawa, K., Yoshikawa, M., and Fujita, T. (2008). Epigenetic regulation of BMP7 in the regenerative response to ischemia. J. Am. Soc. Nephrol. 19, 1311-1320. doi: 10.1681/ASN.2007091040.
36. Marumo, T., Hishikawa, K., Yoshikawa, M., Hirahashi, J., Kawachi, S., and Fujita, T. (2010). Histone deacetylase modulates the proinflammatory and-fibrotic changes in tubulointerstitial injury. Am. J. Physiol. Renal Physiol. 298:F133-F141. doi: 10.1152/ajprenal.00400.2009.
37. Mauer, S. M., Steffes, M. W., Ellis, E. N., Sutherland, D. E., Brown, D. M., and Goetz, F. C. (1984). Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 74, 1143-1155. doi: 10.1172/JCI111523.
38. Miller, T. A., Witter, D. J., and Belvedere, S. (2003). Histone deacetylase inhibitors. J. Med. Chem. 46, 5097-5116. doi: 10.1021/jm0303094.
39. Minucci, S., and Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51. doi: 10.1038/nrc1779.
40. Mishra, N., Brown, D. R., Olorenshaw, I. M., and Kammer, G. M. (2001). Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. U.S.A. 98, 2628-2633. doi: 10.1073/pnas.051507098.
41. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., and Gilkeson, G. S. (2003). Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552. doi: 10.1172/JCI16153.
42. Neilson, E. G. (2006). Mechanisms of disease: fibroblasts-a new look at an old problem. Nat. Clin. Pract. Nephrol. 2, 101-108. doi: 10.1038/ncpneph0093.
43. Noh, H., Oh, E. Y., Seo, J. Y., Yu, M. R., Kim, Y. O., Ha, H., et al. (2009). Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol. 297, F729-F739. doi: 10.1152/ajprenal.00086.2009.
44. Novitskaya, T., McDermott, L., Zhang, K. X., Chiba, T., Paueksakon, P., Hukriede, N. A., et al. (2014). A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Am. J. Physiol. Renal Physiol. 306, F496-F504. doi: 10.1152/ajprenal.00534.2013.
45. Pang, M., Kothapally, J., Mao, H., Tolbert, E., Ponnusamy, M., Chin, Y. E., et al. (2009). Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 297, F996-F1005. doi: 10.1152/ajprenal.00282.2009.
46. Pang, M., Ma, L., Liu, N., Ponnusamy, M., Zhao, T. C., Yan, H., et al. (2011). Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins. J. Cell. Biochem. 112, 2138-2148. doi: 10.1002/jcb.23135.
47. Pang, M., and Zhuang, S. (2010). Histone deacetylase: a potential therapeutic target for fibrotic disorders. J. Pharmacol. Exp. Ther. 335, 266-272. doi: 10.1124/jpet.110.168385.
48. Peters, D. J., and Sandkuijl, L. A. (1992). Genetic heterogeneity of polycystic kidney disease in Europe. Contrib. Nephrol. 97, 128-139.
49. Ponnusamy, M., Zhou, X., Yan, Y., Tang, J., Tolbert, E., Zhao, T. C., et al. (2014). Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J. Pharmacol. Exp. Ther. 350, 243-256. doi: 10.1124/jpet.113.212076.
50. Ramakrishnan, S., and Pili, R. (2013). Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 19, 333-340. doi: 10.1097/PPO.0b013e3182a09e07.
51. Regna, N. L., Chafin, C. B., Hammond, S. E., Puthiyaveetil, A. G., Caudell, D. L., and Reilly, C. M. (2014). Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin. Immunol. 151, 29-42. doi: 10.1016/j.clim.2014.01.002.
52. Remiszewski, S. W. (2002). Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Discov. Devel. 5, 487-499.
53. Selinger, C. I., Cooper, W. A., Al-Sohaily, S., Mladenova, D. N., Pangon, L., Kennedy, C. W., et al. (2011). Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J. Thorac. Oncol. 6, 1179-1189. doi: 10.1097/JTO.0b013e31821b4ce0.
54. Shapiro, R., Jordan, M., Scantlebury, V. P., Vivas, C., Gritsch, H. A., Rao, A. S., et al. (1994). Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin. Transpl. 8, 229-236.
55. Spencer, V. A., and Davie, J. R. (1999). Role of covalent modifications of histones in regulating gene expression. Gene 240, 1-12.
56. Takahashi, I., Miyaji, H., Yoshida, T., Sato, S., and Mizukami, T. (1996). Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J. Antibiot. 49, 453-457.
57. Tang, J., Yan, Y., Zhao, T. C., Bayliss, G., Yan, H., and Zhuang, S. (2013). Class I histone deacetylase activity is required for proliferation of renal epithelial cells. Am. J. Physiol. Renal Physiol. 305, F244-F254. doi: 10.1152/ajprenal.00126.2013.
58. Tao, R., and Hancock, W. W. (2007). Regulating regulatory T cells to achieve transplant tolerance. HBPD INT 6, 348-357.
59. Thivierge, C., Kurbegovic, A., Couillard, M., Guillaume, R., Cote, O., and Trudel, M. (2006). Overexpression of PKD1 causes polycystic kidney disease. Mol. Cell. Biol. 26, 1538-1548. doi: 10.1128/MCB.26.4.1538-1548.2006.
60. Turner, B. M. (1993). Decoding the nucleosome. Cell. 75, 5-8.
61. Van Beneden, K., Geers, C., Pauwels, M., Mannaerts, I., Wissing, K. M., Van Den Branden, C., et al. (2013). Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol. Appl. Pharmacol. 271, 276-284. doi: 10.1016/j.taap.2013.05.013.
62. Van Bodegom, D., Saifudeen, Z., Dipp, S., Puri, S., Magenheimer, B. S., Calvet, J. P., et al. (2006). The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J. Biol. Chem. 281, 31234-31244.
63. Van Lint, C., Emiliani, S., and Verdin, E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-253.
64. Wang, X., Liu, J., Zhen, J., Zhang, C., Wan, Q., Liu, G., et al. (2014). Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney Int. 86, 712-725. doi: 10.1038/ki.2014.111.
65. West, A. C., and Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39. doi: 10.1172/JCI69738.
66. Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210. doi: 10.1002/path.2277.
67. Xia, S., Li, X., Johnson, T., Seidel, C., Wallace, D. P., and Li, R. (2010). Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 137, 1075-1084. doi: 10.1242/dev.049437.
68. Yamaguchi, T., Hempson, S. J., Reif, G. A., Hedge, A. M., and Wallace, D. P. (2006). Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J. Am. Soc. Nephrol. 17, 178-187. doi: 10.1681/ASN.2005060645.
69. Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V., and Bonventre, J. V. (2010). Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16, 535-543, 531p following 143. doi: 10.1038/nm.2144.
70. Zhang, M. Z., Wang, Y., Paueksakon, P., and Harris, R. C. (2014). Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63, 2063-2072. doi: 10.2337/db13-1279.
71. Zhong, Y., Chen, E. Y., Liu, R., Chuang, P. Y., Mallipattu, S. K., Tan, C. M., et al. (2013). Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J. Am. Soc. Nephrol. 24, 801-811. doi: 10.1681/ASN.2012060590.
72. Zhou, X., Fan, L. X., Sweeney, W. E. Jr., Denu, J. M., Avner, E. D., and Li, X. (2013). Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J. Clin. Invest. 123, 3084-3098. doi: 10.1172/JCI64401.